Regeneron Pharmaceuticals REGN has outperformed the market over the past 20 years by 14.22% on an annualized basis producing an average annual return of 22.54%. Currently, Regeneron Pharmaceuticals ...

Dupixent approved by FDA for bullous pemphigoid, offering a new option for adults with the rare autoimmune skin disease ...

-Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning bid of $256 million, a company spokesperson told Reuters on Monday ...

Regeneron Pharmaceuticals has declined to submit a new bid for genetic testing company 23andMe exceeding its original winning ...

The partnership was teased in a brief video posted on Monday by Meta CTO Andrew Bosworth, showing the logos of both companies but offering no glimpse of the new product.

The Regeneron Pharmaceuticals Inc.-Bond has a maturity date of 9/15/2050 and offers a coupon of 2.8000%. The payment of the coupon will take place 2,0 times per biannual on the 15.03.. At the ...

Visit a quote page and your recently viewed tickers will be displayed here.